Keyphrases
Genetic Variants
100%
Review Topic
100%
Genotype-guided Antiplatelet Therapy
100%
De-escalation Therapy
66%
Technological Progress
33%
Evidence Support
33%
Bleeding Risk
33%
Dual Antiplatelet Therapy
33%
Clinical Efficacy
33%
Implementation Barriers
33%
Allelic Variants
33%
Clopidogrel
33%
Drug Metabolism
33%
Ticagrelor
33%
Prasugrel
33%
CYP2C19
33%
Antiplatelet Agents
33%
Drug Selection
33%
Clinical Safety
33%
Optimized Dosing
33%
Genotype-guided
33%
Recurrent Ischemic Events
33%
Individual Drug Response
33%
Pharmacogenomics
33%
Inter-individual Variability
33%
Ischemic Events
33%
Antiplatelet Treatment
33%
INIS
patients
100%
therapy
100%
reviews
100%
genotype
100%
drugs
60%
genetics
60%
risks
40%
ischemia
40%
safety
20%
hospitals
20%
metabolism
20%
barriers
20%
enzymes
20%
implementation
20%
Neuroscience
Metabolic Pathway
100%
Clopidogrel
100%
Antiplatelet Drug
100%
Cytochrome P450 2C19
100%
Ticagrelor
100%
Prasugrel
100%
Biochemistry, Genetics and Molecular Biology
Genotyping
100%
Genetic Divergence
100%
Enzyme
33%
Pharmacogenomics
33%
Drug Response
33%
Drug Metabolism
33%
Clopidogrel
33%
CYP2C19
33%
Prasugrel
33%
Medicine and Dentistry
Antiplatelet
100%
Drug Response
33%
Clopidogrel
33%
Drug Metabolism
33%
CYP2C19
33%
Antiplatelet Drug
33%
Pharmacogenomics
33%
Ticagrelor
33%
Prasugrel
33%
Pharmacology, Toxicology and Pharmaceutical Science
Antiplatelet
100%
Pharmacogenomics
33%
Drug Metabolism
33%
CYP2C19
33%
Clopidogrel
33%
Antithrombocytic Agent
33%
Prasugrel
33%
Ticagrelor
33%